Abstract
During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Keywords: Multidrug resistance, P-gp inhibitor, development
Anti-Cancer Agents in Medicinal Chemistry
Title: Recent Advances in the Development of P-gp Inhibitors
Volume: 9 Issue: 4
Author(s): Christiane Baumert and Andreas Hilgeroth
Affiliation:
Keywords: Multidrug resistance, P-gp inhibitor, development
Abstract: During the last decades multidrug resistance (MDR) emerged as main problem in the anti-cancer therapy with cytostatically active agents. Classical as well as recently developed cytostatics develop the phenomenon of loosing activity in former drug-sensitive cells. Although MDR is a multifactorial process, the main obstacle is the expression of multidrug-efflux pumps that lowers the intracellular drug levels. P-glycoprotein (P-gp) is the longest identified efflux pump. As the attempt to overcome MDR by the use of inhibitors of the efflux pump activities turned out as most promising effect, the development of P-gp inhibitors has been a challenge for medicinal chemists. The article reviews the advances in P-gp inhibitor development by focussing on structure-activity relationships in the different compound classes to document improvements. The success has been the reduction of cytotoxic properties. The undesired activities could be much lowered in the case of compound classes that were derived from pharmacologically active drugs. Undesired drug interactions and limited in vivo activities are still a problem.
Export Options
About this article
Cite this article as:
Baumert Christiane and Hilgeroth Andreas, Recent Advances in the Development of P-gp Inhibitors, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (4) . https://dx.doi.org/10.2174/1871520610909040415
DOI https://dx.doi.org/10.2174/1871520610909040415 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights
Current Neuropharmacology Short Bioactive Marine Oligosaccharides: Diving into Recent Literature
Current Biotechnology Translational Molecular Imaging in Drug Development: Current Status and Challenges
Current Medical Imaging Regioselective Amination of 3-Bromoindolylmaleimide with Amines
Letters in Organic Chemistry Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment
Current Topics in Medicinal Chemistry Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates
Current Topics in Medicinal Chemistry Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Introduction: Hepatocyte Growth Factor and Met Receptor, from Discovery to Therapeutic Implications
Current Signal Transduction Therapy Computational Docking Studies of Novel Heterocyclic Carboxamides as Potential PI3Kα Inhibitors
Letters in Drug Design & Discovery From Data Processing to Multivariate Validation - Essential Steps in Extracting Interpretable Information from Metabolomics Data
Current Pharmaceutical Biotechnology Editorial [Hot topic: Baculovirus: A Promising Vector for Gene Therapy? (Guest Editor: Yu-Chen Hu)]
Current Gene Therapy Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology Antiangiogenesis in Myelodysplastic Syndrome
Current Cancer Drug Targets Editorial (Thematic Issue: Perspectives on Strategies for Overcoming Cancer Therapy Resistance)
Current Protein & Peptide Science Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion
Mini-Reviews in Medicinal Chemistry Nifurtimox Hampered the Progression of Astroglioma <i>In vivo Via</i> Manipulating the AKT-GSK3β axis
Current Molecular Medicine Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy
Current Medicinal Chemistry